Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
January 31, 2023 at 12:40 pm IST
Share
Hester Biosciences Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 749.44 million compared to INR 556.89 million a year ago. Revenue was INR 793.35 million compared to INR 584.66 million a year ago. Net income was INR 111.86 million compared to INR 84.84 million a year ago. Basic earnings per share from continuing operations was INR 14.29 compared to INR 9.79 a year ago.
For the nine months, sales was INR 1,987.92 million compared to INR 1,785.37 million a year ago. Revenue was INR 2,107.55 million compared to INR 1,850.86 million a year ago. Net income was INR 220.96 million compared to INR 315.97 million a year ago. Basic earnings per share from continuing operations was INR 26.24 compared to INR 35.83 a year ago.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
HESTER BIOSCIENCES LIMITED 